Literature DB >> 33707901

Renal Dysfunction in Cirrhosis: Critical Care Management.

Akila Rajakumar1, Ellango Appuswamy2, Ilankumaran Kaliamoorthy1, Mohamed Rela3.   

Abstract

Cirrhotic patients with manifestations of the end-stage liver disease have a high risk for developing renal dysfunction even with minor insults. The development of renal dysfunction increases the morbidity and mortality of these patients. Causes of renal dysfunction in cirrhotics can be due to hepatorenal syndrome (HRS) or acute kidney injury (AKI) resulting from prerenal, renal, and postrenal causes. Development of pretransplant renal dysfunction has been shown to affect post-liver transplantation outcomes. Early detection and aggressive strategies for the prevention of further progression of renal dysfunction seem to decrease the morbidity and improve survival in this group of patients. This article aims to outline the pathogenesis of renal dysfunction in cirrhosis, etiological factors, and evaluation of renal dysfunction, strategies for aggressive therapy for renal dysfunction, the indications of renal replacement therapy (RRT) in this group of patients, and the various modalities of RRT with their merits and demerits. A thorough understanding of the pathogenesis, early detection, and aggressive corrective measures for AKI can prevent further progression. In conclusion, a good knowledge of treatment modalities available for renal dysfunction in cirrhosis and institution of timely interventions can significantly improve survival in this group of patients. KEY MESSAGES: Development of renal dysfunction in cirrhotics increases the morbidity and mortality of these patients and results in poor outcomes after liver transplantation. Early detection and aggressive strategies for the prevention of further progression of renal dysfunction seem to decrease the morbidity and improve survival in this group of patients. HOW TO CITE THIS ARTICLE: Rajakumar A, Appuswamy E, Kaliamoorthy I, Rela M. Renal Dysfunction in Cirrhosis: Critical Care Management. Indian J Crit Care Med 2021;25(2):207-214.
Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.

Entities:  

Keywords:  Acute kidney injury in cirrhosis; Dialysis in cirrhosis; Hepatorenal syndrome; Renal dysfunction in cirrhosis; Renal replacement therapy in cirrhosis; Volume overload in cirrhosis

Year:  2021        PMID: 33707901      PMCID: PMC7922436          DOI: 10.5005/jp-journals-10071-23721

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


  107 in total

1.  Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial.

Authors:  Bradley A Bart; Andrew Boyle; Alan J Bank; Inder Anand; Maria Teresa Olivari; Mark Kraemer; Shari Mackedanz; Paul A Sobotka; Mike Schollmeyer; Steven R Goldsmith
Journal:  J Am Coll Cardiol       Date:  2005-11-04       Impact factor: 24.094

2.  Association of AKI with mortality and complications in hospitalized patients with cirrhosis.

Authors:  Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

Review 3.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 4.  Hepatorenal syndrome.

Authors:  Pere Ginès; Mónica Guevara; Vicente Arroyo; Juan Rodés
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

5.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Authors:  Marta Martín-Llahí; Marie-Noëlle Pépin; Mónica Guevara; Fernando Díaz; Aldo Torre; Alberto Monescillo; Germán Soriano; Carlos Terra; Emilio Fábrega; Vicente Arroyo; Juan Rodés; Pere Ginès
Journal:  Gastroenterology       Date:  2008-02-14       Impact factor: 22.682

6.  Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.

Authors:  R H Sterns; J D Cappuccio; S M Silver; E P Cohen
Journal:  J Am Soc Nephrol       Date:  1994-02       Impact factor: 10.121

Review 7.  Acute renal failure in patients with cirrhosis: perspectives in the age of MELD.

Authors:  Richard Moreau; Didier Lebrec
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.

Authors:  Sergio Neri; Davide Pulvirenti; Mariano Malaguarnera; Bruno M Cosimo; Gaetano Bertino; Luca Ignaccolo; Sebasiano Siringo; Pietro Castellino
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

9.  Immunomodulatory effect of continuous venovenous hemofiltration during sepsis: preliminary data.

Authors:  Giuseppe Servillo; Maria Vargas; Antonio Pastore; Alfredo Procino; Michele Iannuzzi; Alfredo Capuano; Andrea Memoli; Eleonora Riccio; Bruno Memoli
Journal:  Biomed Res Int       Date:  2013-07-23       Impact factor: 3.411

10.  Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis.

Authors:  Francesco Salerno; Roberta J Navickis; Mahlon M Wilkes
Journal:  BMC Gastroenterol       Date:  2015-11-25       Impact factor: 3.067

View more
  2 in total

Review 1.  Management of acute renal replacement therapy in critically ill cirrhotic patients.

Authors:  Jimena Del Risco-Zevallos; Alicia Molina Andújar; Gastón Piñeiro; Enric Reverter; Néstor David Toapanta; Miquel Sanz; Miquel Blasco; Javier Fernández; Esteban Poch
Journal:  Clin Kidney J       Date:  2022-01-28

Review 2.  Nephroprotective Plants: A Review on the Use in Pre-Renal and Post-Renal Diseases.

Authors:  Mario Adrián Tienda-Vázquez; Zoé P Morreeuw; Juan Eduardo Sosa-Hernández; Anaberta Cardador-Martínez; Ernesto Sabath; Elda M Melchor-Martínez; Hafiz M N Iqbal; Roberto Parra-Saldívar
Journal:  Plants (Basel)       Date:  2022-03-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.